Breaking News

PharmaForm To Manufacture Corcept Drug

Will serve as the primary commercial manufacturer for Korlym

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Corcept Therapeutics has selected PharmaForm as its primary commercial manufacturer for Korlym. The FDA approved Corcept’s Korlym in February for patients with endogenous Cushing’s syndrome.

PharmaForm provides development and manufacturing services for the pharmaceutical and biotech industries. The two companies have worked together for the past several years.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters